News

July 13, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

June 17, 2023

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

June 7, 2023

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 22, 2023

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

May 8, 2023

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

May 5, 2023

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

May 2, 2023

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

April 24, 2023

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

April 18, 2023

Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023